Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share. These options expire on June 10, 2036 and vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director George M. Jenkins received a grant of stock options for 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. They vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, subject to his continued service. After this grant, he holds 3,000 options directly.
Palvella Therapeutics director Elaine J. Heron received a grant of stock options for 3,000 shares of common stock. These options carry an exercise price of $102.19 per share and expire on June 10, 2036.
The options vest upon the earlier of the first anniversary of the June 10, 2026 grant date or the company’s next annual meeting of stockholders, subject to Heron’s continued service through the applicable vesting date. Following this grant, Heron holds 3,000 stock options directly.
PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of 102.1900 per share and expire on 2036-06-10.
These options vest upon the earlier of the first anniversary of the 2026-06-10 grant date or the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related grant, Doux holds 3,000 stock options directly.
Palvella Therapeutics director Todd C. Davis received a new stock option grant. He was awarded options to buy 3,000 shares of common stock at an exercise price of $102.19 per share, expiring on June 10, 2036. The options vest on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. All 3,000 options are held directly after this transaction. The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual meeting of stockholders, in each case requiring his continued service through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin reported option exercises and share sales in the company’s stock. On May 20, 2026, she exercised stock options for 2,154 shares at $7.14 per share and 2,148 shares at $9.08 per share, acquiring 4,302 shares of common stock.
That same day, she sold a total of 4,302 common shares in open‑market transactions at weighted average prices of about $110.35, $111.30, and $111.90. The filing shows she held 0 common shares directly after these transactions. The sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on August 19, 2025, during an open trading window.
Palvella Therapeutics filed a Rule 144 notice reporting the proposed sale of Common Stock on 05/20/2026 associated with a stock option exercise to the issuer for cash. The filing lists broker details and transaction references including $475,630.84 and an aggregate figure 14,342,844 alongside prior sale entries by Kathleen Goin on 03/18/2026 and 04/15/2026 with amounts $507,611.05 and $547,398.96.
Palvella Therapeutics, Inc. reported new clinical data from its Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN™ 3.9% rapamycin gel in serious, rare vascular malformations. In SELVA, all 13 participants aged 6–11 years were rated “Much Improved” or “Very Much Improved” on the Microcystic Lymphatic Malformation Investigator Global Assessment at Week 24, with a mean improvement of +2.46 and p<0.001. Among 23 patients with moderate or worse leaking or bleeding at baseline, 87% achieved these top response categories with a mean improvement of +2.48. All 43 SELVA participants completing the efficacy period were at least somewhat satisfied on the TSQM-9, and 84% reported high satisfaction levels. Blinded review showed minimal change during the 8-week run-in and a 3.4-point mean mLM-MCSS improvement after 24 weeks, representing 48% of the maximum potential improvement. TOIVA showed statistically significant reductions in cVM-MCSS Height and Appearance at all time points, with Week 24 mean reductions of 1.50 and 1.43 points (p<0.001). Palvella plans to submit a New Drug Application for microcystic lymphatic malformations in the second half of 2026, targeting potential approval in the first half of 2027, and to start a Phase 3 trial in cutaneous venous malformations in the second half of 2026. QTORIN™ rapamycin holds FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations for microcystic lymphatic malformations and Fast Track for cutaneous venous malformations.
Palvella Therapeutics reported new efficacy and patient-experience data from its Phase 2 TOIVA trial of QTORIN™ rapamycin in cutaneous venous malformations. Among patients who had bleeding at baseline, 100% (4/4) showed statistically significant improvement on the clinician-rated cVM-IGA Bleeding scale at Week 12, with a mean change of +2.5 points (p=0.003), and all were rated “Much Improved” or “Very Much Improved.” At the same time point, 100% of these patients reported being “satisfied” or “very satisfied” with treatment. Baseline qualitative interviews highlighted substantial pain, functional limitations, social and work impacts, and emotional distress, underscoring the broad quality-of-life burden in this rare disease where there are currently no FDA-approved therapies.